Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial

Autor: Raches Ella, Siddarth Reddy, William Blackwelder, Varsha Potdar, Pragya Yadav, Vamshi Sarangi, Vinay K Aileni, Suman Kanungo, Sanjay Rai, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Redkar, Satyajit Mohapatra, Anil Pandey, Pajanivel Ranganadin, Raghavendra Gumashta, Manish Multani, Shameem Mohammad, Parul Bhatt, Laxmi Kumari, Gajanan Sapkal, Nivedita Gupta, Priya Abraham, Samiran Panda, Sai Prasad, Balram Bhargava, Krishna Ella, Krishna Mohan Vadrevu, P. Aggarwal, V. Aglawe, A. Ali, N. Anand, N. Awad, V. Bafna, G. Balasubramaniyam, A. Bandkar, P. Basha, V. Bharge, A. Bhate, S. Bhate, V. Bhavani, R. Bhosale, DV Chalapathy, C. Chaubal, D. Chaudhary, A. Chavan, P. Desai, D. Dhodi, S. Dutta, R. Garg, K. Garg, M. George, P. Goyal, R. Guleria, S. Gupta, M. Jain, M.K. Jain, S. Jindal, M. Kalra, S. Kant, P. Khosla, P. Kulkarni, P. Kumar, Y. Kumar, A. Majumdar, P. Meshram, V. Mishra, S. Mohanty, J. Nair, S. Pandey, S.K. Panigrahi, B. Patil, V. Patil, P. Rahate, V. Raj, S. Ramanand, K. Rami, B. Ramraj, S. Rane, E.V. Rao, N. Rao, R. Raphael, G. Reddy, V. Redkar, S. Redkar, A. Sachdeva, J. Saha, J. Sahoo, P. Sampath, A. Savith, M. Shah, L. Shanmugam, R. Sharma, P. Sharma, D. Sharma, A. Singh, J. Singh, P. Singh, S. Sivaprakasam, S. Subramaniam, D. Sudheer, S. Tandon, M. Tariq, V. Tripathi, M. Vable, R. Verma, S. Waghmare

Publikováno v: Lancet (London, England)

Summary Background We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults. Methods W

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::256b5183e10ed0b5271e83b90c24e6e2
https://pubmed.ncbi.nlm.nih.gov/34774194